SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 733.04-1.2%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bocaburgerman who wrote (192)11/6/1997 9:46:00 AM
From: scaram(o)uche  Read Replies (2) of 3559
 
Winston:

Thanks!

I like the news too, and I agree with MZ that constipation may be a good revenue angle. However, I'm confused...... we're getting signals that *both* BDNF and NT-3 will be used for gastrointestinal, NT-3 for Parkinson's (and other) and BDNF for ????.

I think that they've decided to use NT-3 for the gastro indication observed using BDNF. This still doesn't tell us anything about the subset of ALS that is of interest for further BDNF study. At least I don't think it does. :-)

Cheers! Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News